ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

(2017) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers

(2017) Helena A. Yu et al.   Journal of the National Comprehensive Cancer Network

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

(2016) Dongsheng Wang et al.   CLINICAL CANCER RESEARCH

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

(2016) F. J. Sanchez-Martin et al.   CLINICAL CANCER RESEARCH

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2016) Robert Pirker   CURRENT OPINION IN ONCOLOGY

Drugging the addict: non‐oncogene addiction as a target for cancer therapy

(2016) Remco Nagel et al.   EMBO REPORTS

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

(2016) Hampig Raphael Kourie et al.   Expert Opinion on Drug Metabolism & Toxicology

Targeting the EGFR T790M mutation in non-small-cell lung cancer

(2016) Nicola Normanno et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3

(2016) Keman Zhang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation

(2016) Silvia La Monica et al.   Journal of Thoracic Oncology

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients

(2016) Tiziana Vavalà et al.   LUNG CANCER

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

(2016) Gábor Tóth et al.   mAbs

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

(2016) Magdalena Malm et al.   mAbs

High-throughput imaging: Focusing in on drug discovery in 3D

(2016) Linfeng Li et al.   METHODS

Past, Present, and Future of Targeting Ras for Cancer Therapies

(2016) Zhi Tan et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

(2016) Yoshihisa Kobayashi et al.   MOLECULAR CANCER THERAPEUTICS

Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer

(2016) Ying Sun et al.   ONCOLOGY REPORTS

Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer

(2016) I. De Pauw et al.   PHARMACOLOGY & THERAPEUTICS

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model

(2016) Sritama Nath et al.   PHARMACOLOGY & THERAPEUTICS

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

(2016) Sabrina Arena et al.   Science Translational Medicine

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

(2016) Huiping Shi et al.   TUMOR BIOLOGY

Osimertinib making a breakthrough in lung cancer targeted therapy

(2016) Haijun Zhang   OncoTargets and Therapy

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance

(2016) Qiong Lu et al.   Oncotarget

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

(2016) Xiaochun Liu et al.   Oncotarget

PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells

(2016) Xin-min Zhao et al.   Oncotarget

Uncoupling of EGFR–RAS signaling and nuclear localization of YBX1 in colorectal cancer

(2016) F Roßner et al.   Oncogenesis

Role of targeted therapy in metastatic colorectal cancer

(2016) Yoshihito Ohhara et al.   World Journal of Gastrointestinal Oncology

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance

(2016) E. Allen Sickmier et al.   PLoS One

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies

(2015) Bingliang Fang   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

HER3/ErbB3, an emerging cancer therapeutic target

(2015) Ningyan Zhang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer

(2015) Alma D. Campos-Parra et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

ERBB4 is over-expressed in human colon cancer and enhances cellular transformation

(2015) Christopher S. Williams et al.   CARCINOGENESIS

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

(2015) S. Arena et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

HER2-positive metastatic breast cancer: A changing scenario

(2015) G. Mustacchi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer

(2015) Masayuki Takeda et al.   CURRENT CANCER DRUG TARGETS

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

(2015) R. Pagliarini et al.   EMBO REPORTS

Phosphorylation of GlutathioneS-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells

(2015) Tatsunori Okamura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

(2015) Yuliana Yosaatmadja et al.   JOURNAL OF STRUCTURAL BIOLOGY

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

(2015) Eiki Ichihara et al.   Journal of Thoracic Oncology

Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis

(2015) Sabrina Rossi et al.   Molecular Diagnosis & Therapy

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating ERBB4 mutations in non-small cell lung cancer

(2015) K J Kurppa et al.   ONCOGENE

The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer

(2015) E. J. Diver et al.   ONCOLOGIST

Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models

(2015) Hao Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer

(2015) Xiaohong Pu et al.   PATHOLOGY RESEARCH AND PRACTICE

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

(2015) Dario Presutti et al.   PLoS One

High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts

(2015) Albin Rudisch et al.   PLoS One

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience

(2015) Zsuzsanna Varga et al.   PLoS One

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors

(2015) Jéssica Gomes et al.   OncoTargets and Therapy

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

(2015) Biswanath Majumder et al.   Nature Communications

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

(2015) Ijeoma Adaku Umelo et al.   Oncotarget

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

(2015) Friederike Braig et al.   Oncotarget

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices

(2015) Emma J. Davies et al.   Scientific Reports

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

(2015) Alessia Noto et al.   Oncotarget

Oncogene addiction: resetting the safety switch?

(2015) Yulin Li et al.   Oncotarget

Regulation of ERBB3/HER3 signaling in cancer

(2015) Kalpana Mujoo et al.   Oncotarget

Role of erbB3 receptors in cancer therapeutic resistance

(2014) Y. Lee et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development

(2014) Christine Unger et al.   ADVANCED DRUG DELIVERY REVIEWS

A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition

(2014) Yong Fang et al.   BIOCHEMICAL JOURNAL

Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo

(2014) John A. Hickman et al.   Biotechnology Journal

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

(2014) C. H. Kugel et al.   CANCER RESEARCH

HER2 aberrations in cancer: Implications for therapy

(2014) Min Yan et al.   CANCER TREATMENT REVIEWS

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer

(2014) C. Amendt et al.   CLINICAL CANCER RESEARCH

Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth

(2014) Sung Keun Jung et al.   MOLECULAR CARCINOGENESIS

IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction

(2014) C Rupp et al.   ONCOGENE

Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development

(2014) Jason E. Ekert et al.   PLoS One

3-Dimensional Culture Systems for Anti-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems

(2014) Amy L. Howes et al.   PLoS One

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Three-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation

(2014) Hamsa Jaganathan et al.   Scientific Reports

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy

(2014) Robert Torka et al.   NEOPLASIA

Targeting MET Amplification as a New Oncogenic Driver

(2014) Hisato Kawakami et al.   Cancers

Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors

(2013) Feng Zhao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

(2013) Nikolaos Ioannou et al.   BMC CANCER

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

(2013) Claudia Esposito et al.   CANCER BIOLOGY & THERAPY

One mouse, one patient paradigm: New avatars of personalized cancer therapy

(2013) Prerna Malaney et al.   CANCER LETTERS

Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery

(2013) Michael P. Lisanti et al.   CELL CYCLE

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2013) P. LoRusso et al.   CLINICAL CANCER RESEARCH

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

(2013) Jingcao Huang et al.   Molecular Cancer

Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments

(2013) Felicitas Merz et al.   NEURO-ONCOLOGY

Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer

(2013) L K Nottingham et al.   ONCOGENE

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines

(2013) Anna C. Luca et al.   PLoS One

A Simple High-Content Cell Cycle Assay Reveals Frequent Discrepancies between Cell Number and ATP and MTS Proliferation Assays

(2013) Grace Ka Yan Chan et al.   PLoS One

Activating Mutations in HER2 : Neu Opportunities and Neu Challenges

(2013) Britta Weigelt et al.   Cancer Discovery

A view on EGFR-targeted therapies from the oncogene-addiction perspective

(2013) Rolando Perez et al.   Frontiers in Pharmacology

Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways

(2012) Q Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Oncogene addiction

(2012) Jeffrey Settleman   CURRENT BIOLOGY

Three-dimensional cell culture: the missing link in drug discovery

(2012) Susan Breslin et al.   DRUG DISCOVERY TODAY

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

(2012) Kang-Yi Su et al.   JOURNAL OF CLINICAL ONCOLOGY

The practicalities of using tissue slices as preclinical organotypic breast cancer models

(2012) Deborah L Holliday et al.   JOURNAL OF CLINICAL PATHOLOGY

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination

(2012) Lydia M Balz et al.   JOURNAL OF PATHOLOGY

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

(2012) Xianhua Wu et al.   Journal of Translational Medicine

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

(2012) Y. Pan et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells

(2012) Martin Bezler et al.   Molecular Oncology

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

HER2—a good addiction

(2012) Lisa A. Carey   Nature Reviews Clinical Oncology

Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures

(2012) Sandrine Eimer et al.   NEURO-ONCOLOGY

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma

(2012) Andrej Pala et al.   Cancers

Differences underlying EGFR and HER2 oncogene addiction

(2011) Anthony C. Faber et al.   CELL CYCLE

A growing family: Adding mutated Erbb4 as a novel cancer target

(2011) Udo Rudloff et al.   CELL CYCLE

Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer

(2011) A. Beji et al.   CLINICAL CANCER RESEARCH

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

(2011) Davide Torti et al.   EMBO Molecular Medicine

StellaTUM: current consensus and discussion on pancreatic stellate cell research

(2011) Mert Erkan et al.   GUT

Microenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis

(2011) Y. Carmi et al.   JOURNAL OF IMMUNOLOGY

Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5

(2011) R. Rossin et al.   JOURNAL OF NUCLEAR MEDICINE

IBC's 21stAnnual Antibody Engineering and 8thAnnual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

(2011) Samantha O Arnett et al.   mAbs

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases

(2011) Andrew J. Shih et al.   Cancers

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer

(2011) Carmen Berasain et al.   Cancers

Epidermal Growth Factor Receptor in Pancreatic Cancer

(2011) Melissa Oliveira-Cunha et al.   Cancers

Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay

(2010) Weidong Huang et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

(2010) Qing Sheng et al.   CANCER CELL

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

(2010) Matthew D. Galsky et al.   INVESTIGATIONAL NEW DRUGS

Multicellular tumor spheroids: An underestimated tool is catching up again

(2010) Franziska Hirschhaeuser et al.   JOURNAL OF BIOTECHNOLOGY

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies

(2010) Inge A M de Graaf et al.   Nature Protocols

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

(2010) S Wang et al.   ONCOGENE

Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors

(2010) V. Vaira et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

(2010) Dhara N. Amin et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

(2010) Merel Gijsen et al.   PLOS BIOLOGY

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice

(2010) Laura P. Stabile et al.   Cancers

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

The PKB/AKT Pathway in Cancer

(2009) Amancio Carnero   CURRENT PHARMACEUTICAL DESIGN

Improved reproducibility in preparing precision-cut liver tissue slices

(2009) Martina Zimmermann et al.   CYTOTECHNOLOGY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

(2009) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY

Spheroid-based drug screen: considerations and practical approach

(2009) Juergen Friedrich et al.   Nature Protocols

Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer

(2009) V. Roy et al.   ONCOLOGIST

Synthetic lethality: a framework for the development of wiser cancer therapeutics

(2009) William G Kaelin   Genome Medicine

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

ErbBs in lung cancer

(2008) Sreenath V. Sharma et al.   EXPERIMENTAL CELL RESEARCH

Ligand-induced ErbB receptor dimerization

(2008) Mark A. Lemmon   EXPERIMENTAL CELL RESEARCH

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of ErbB4 in Breast Cancer

(2008) Maria Sundvall et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas

(2008) Jian Yi Li et al.   JOURNAL OF NEURO-ONCOLOGY

Transforming Growth Factor-  Signaling-Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion

(2008) N. Cheng et al.   MOLECULAR CANCER RESEARCH

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab

(2008) M Pickl et al.   ONCOGENE

Topological Analysis of MAPK Cascade for Kinetic ErbB Signaling

(2008) Takashi Nakakuki et al.   PLoS One

Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression

(2007) Seungchan Yang et al.   EXPERIMENTAL CELL RESEARCH